These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

675 related articles for article (PubMed ID: 26212075)

  • 1. Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt.
    Berres ML; Lehmann J; Jansen C; Görtzen J; Meyer C; Thomas D; Zimmermann HW; Kroy D; Schumacher F; Strassburg CP; Sauerbruch T; Trautwein C; Wasmuth HE; Trebicka J
    Liver Int; 2016 Mar; 36(3):386-94. PubMed ID: 26212075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    Berres ML; Asmacher S; Lehmann J; Jansen C; Görtzen J; Klein S; Meyer C; Strunk HM; Fimmers R; Tacke F; Strassburg CP; Trautwein C; Sauerbruch T; Wasmuth HE; Trebicka J
    J Hepatol; 2015 Feb; 62(2):332-9. PubMed ID: 25457205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating Elastin Fragments Are Not Affected by Hepatic, Renal and Hemodynamic Changes, But Reflect Survival in Cirrhosis with TIPS.
    Nielsen MJ; Lehmann J; Leeming DJ; Schierwagen R; Klein S; Jansen C; Strassburg CP; Bendtsen F; Møller S; Sauerbruch T; Karsdal MA; Krag A; Trebicka J
    Dig Dis Sci; 2015 Nov; 60(11):3456-64. PubMed ID: 26138655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating CXCL10 in cirrhotic portal hypertension might reflect systemic inflammation and predict ACLF and mortality.
    Lehmann JM; Claus K; Jansen C; Pohlmann A; Schierwagen R; Meyer C; Thomas D; Manekeller S; Claria J; Strassburg CP; Trautwein C; Wasmuth HE; Berres ML; Trebicka J
    Liver Int; 2018 May; 38(5):875-884. PubMed ID: 29105936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined transjugular intrahepatic portosystemic shunt and other interventions for hepatocellular carcinoma with portal hypertension.
    Qiu B; Zhao MF; Yue ZD; Zhao HW; Wang L; Fan ZH; He FL; Dai S; Yao JN; Liu FQ
    World J Gastroenterol; 2015 Nov; 21(43):12439-47. PubMed ID: 26604651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shunting branch of portal vein and stent position predict survival after transjugular intrahepatic portosystemic shunt.
    Bai M; He CY; Qi XS; Yin ZX; Wang JH; Guo WG; Niu J; Xia JL; Zhang ZL; Larson AC; Wu KC; Fan DM; Han GH
    World J Gastroenterol; 2014 Jan; 20(3):774-85. PubMed ID: 24574750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk Factors for Hepatic Encephalopathy after Transjugular Intrahepatic Portosystemic Shunt in Patients with Hepatocellular Carcinoma and Portal Hypertension.
    Yao J; Zuo L; An G; Yue Z; Zhao H; Wang L; Liu F
    J Gastrointestin Liver Dis; 2015 Sep; 24(3):301-7. PubMed ID: 26405702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term clinical outcomes in patients with viral hepatitis related liver cirrhosis after transjugular intrahepatic portosystemic shunt treatment.
    Teng D; Zuo H; Liu L; Dong J; Ding L
    Virol J; 2018 Oct; 15(1):151. PubMed ID: 30285813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transjugular intrahepatic portosystemic shunt creation for cirrhotic portal hypertension is well tolerated among patients with portal vein thrombosis.
    Merola J; Fortune BE; Deng Y; Ciarleglio M; Amirbekian S; Chaudhary N; Shanbhogue A; Ayyagari R; Rodriguez-Davalos MI; Teperman L; Charles HW; Sigal SH
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):668-675. PubMed ID: 29462027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between pre-TIPS hepatic hemodynamics and postoperative incidence of hepatic encephalopathy.
    Deng D; Liao MS; Qin JP; Li XA
    Hepatobiliary Pancreat Dis Int; 2006 May; 5(2):232-6. PubMed ID: 16698582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of miRNA-34a as a prognostic biomarker for cirrhotic patients with portal hypertension receiving TIPS.
    Jansen C; Eischeid H; Goertzen J; Schierwagen R; Anadol E; Strassburg CP; Sauerbruch T; Odenthal M; Trebicka J
    PLoS One; 2014; 9(7):e103779. PubMed ID: 25068403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transjugular intrahepatic portosystemic shunt as a bridge to non-hepatic surgery in cirrhotic patients with severe portal hypertension: a systematic review.
    Lahat E; Lim C; Bhangui P; Fuentes L; Osseis M; Moussallem T; Salloum C; Azoulay D
    HPB (Oxford); 2018 Feb; 20(2):101-109. PubMed ID: 29110990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian network-based survival prediction model for patients having undergone post-transjugular intrahepatic portosystemic shunt for portal hypertension.
    Chen R; Luo L; Zhang YZ; Liu Z; Liu AL; Zhang YW
    World J Gastroenterol; 2024 Apr; 30(13):1859-1870. PubMed ID: 38659484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transjugular intrahepatic portosystemic shunt placement for refractory ascites: a single-centre experience.
    Lodato F; Berzigotti A; Lisotti A; Azzaroli F; Mosconi C; Giampalma E; Renzulli M; Cappelli A; Buonfiglioli F; Calvanese C; Zoli M; Golfieri R; Mazzella G
    Scand J Gastroenterol; 2012 Dec; 47(12):1494-500. PubMed ID: 22958120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of technical parameters on transjugular intrahepatic portosystemic shunts utilizing stent grafts.
    Andring B; Kalva SP; Sutphin P; Srinivasa R; Anene A; Burrell M; Xi Y; Pillai AK
    World J Gastroenterol; 2015 Jul; 21(26):8110-7. PubMed ID: 26185383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morbidity and mortality after transjugular intrahepatic portosystemic shunt placement in patients with cirrhosis.
    Dissegna D; Sponza M; Falleti E; Fabris C; Vit A; Angeli P; Piano S; Cussigh A; Cmet S; Toniutto P
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):626-632. PubMed ID: 30550458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APTR is a prognostic marker in cirrhotic patients with portal hypertension during TIPS procedure.
    Yu S; Qi Y; Jiang J; Wang H; Zhou Q
    Gene; 2018 Mar; 645():30-33. PubMed ID: 29274906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble TNF-alpha-receptors I are prognostic markers in TIPS-treated patients with cirrhosis and portal hypertension.
    Trebicka J; Krag A; Gansweid S; Schiedermaier P; Strunk HM; Fimmers R; Strassburg CP; Bendtsen F; Møller S; Sauerbruch T; Spengler U
    PLoS One; 2013; 8(12):e83341. PubMed ID: 24386183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis.
    Han G; Qi X; He C; Yin Z; Wang J; Xia J; Yang Z; Bai M; Meng X; Niu J; Wu K; Fan D
    J Hepatol; 2011 Jan; 54(1):78-88. PubMed ID: 20932597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does Transjugular Intrahepatic Portosystemic Shunt Stent Differentially Improve Survival in a Subset of Cirrhotic Patients?
    Trebicka J
    Semin Liver Dis; 2018 Feb; 38(1):87-96. PubMed ID: 29471569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.